WI241665 2018 GLOBAL ASPIRE TTR Amyloidosis _ Transthyretin Amyloidosis National Registry - a Prospective Non-interventional, Longitudinal, Observational Multicentre Study
试验速览
- 阶段
- 不适用
- 状态
- Enrolling By Invitation
- 发起方
- 入组人数
- 100
- 试验地点
- 1
- 主要终点
- disease progression
研究概览
简要总结
We carry out a prospective non-interventional, longitudinal, observational multicentre registry designed to improve our understanding of the epidemiology of TTR amyloidosis in our country. The main objective of the proposed study is to determine the occurrence of TTR amyloidosis and describe clinical profile of patients in the population of our country.
详细描述
Demographic information, TTR genotype, medical history, family history of the disease, and transplant history are assessed at baseline. On return visits, signs and symptoms of the disease are evaluated, general examinations are conducted, and laboratory data, measures of neurologic and cardiovascular function, and quality of life are assessed according to the standard of care for patients.
Specific Aims and Hypotheses
Our working hypotheses are:
- TTR amyloidosis affects patients in the population of our country;
- there are specific TTR mutations in the population of our country;
- there is genotype-phenotype relationship in hereditary TTR amyloidosis;
- there are risk factors for TTR amyloidosis in the population of our country. These hypotheses will be tested in our specific aims. In aim 1. we will describe the occurrence of TTR amyloidosis in the population of our country, including the hereditary and acquired forms of the disease.
In aim 2. we will determine and characterize high frequency TTR mutations in the population of our country.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Control
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adults over 18 years old with confirmed diagnosis of TTR amyloidosis
排除标准
- •Refusal to participate in the study. Light-chain amyloidosis.
结局指标
主要结局
disease progression
时间窗: From enrollment for at least 12 month
Signs and symptoms of the disease are evaluated, general examinations are conducted, and laboratory data, measures of neurologic and cardiovascular function, and quality of life are assessed according to the standard of care for patients.
次要结局
未报告次要终点
研究者
Monika Gawor-Prokopczyk
PhD
National Institute of Cardiology, Warsaw, Poland
